While it may improve the look of dry or dull lips, there is no strong medical evidence that it can reduce dark lip pigmentation 18
Y.Mietlicki-BaaseE

Recent research and observational reports have highlighted: Self-reported reductions in alcohol cravings among some individuals taking GLP-1 medications Decreases in alcohol consumption noted in limited human studies Reduced alcohol-seeking behavior observed in animal models Researchers have proposed several mechanisms that may help explain these findings, including: Modulation of dopamine signaling within reward-related brain pathways Reduced reinforcement or reward response associated with alcohol intake Altered motivation or craving intensity related to substance use It is important to note that existing studies have significant limitations, such as: Small sample sizes and short study durations Reliance on self-reported alcohol use rather than objective measures A lack of randomized, controlled clinical trials Key context to keep in mind: GLP-1 medications are not approved for the treatment of alcohol use disorder Reported effects vary widely between individuals Current evidence is insufficient to establish causation or clinical benefit Research in this area is ongoing, and no definitive conclusions can be drawn at this time

Not mentioned in Morgan & Morgans FOIA requests was Lillys Zepbound, which has the same active ingredient as Mounjaro and was approved by the FDA on November 8 for weight control
If GHK-Cu were developed as a pharmaceutical drug, its applications would likely be limited to specialized medical fields, such as wound healing and injectable therapies
Key Features Glutathione-Enriched Formula: Helps brighten and enhance skin clarity